Although measures of FGFR4 levels in CRC through IHC remains limited, its elevation in other cancers and early evaluation of its protein levels at the cell surface suggests that FGFR4 should continue to be assessed as a CRC biomarker. This evidence concerns the gene FGFR4 and colorectal carcinoma.